ODM 103
Alternative Names: ODM-103Latest Information Update: 10 Feb 2015
At a glance
- Originator Orion
- Class Antiparkinsonians
- Mechanism of Action Catechol O-methyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 04 Feb 2015 Discontinued - Phase-I for Parkinson's disease (In volunteers) in Germany (PO)
- 01 Sep 2014 Orion Corporation completes a phase I trial in Parkinson's disease (In volunteers) in Germany (NCT01688089)
- 01 Nov 2013 Orion suspends enrolment in a phase I trial in healthy volunteers in Germany (NCT01688089)